Plasmodium falciparum has become resistant to artemisinin
Artemisinin is the first line treatment of uncomplicated falciparum malaria in areas where malaria is endemic, but evidence is emerging that the parasite is becoming resistant to this drug at the Thai-Cambodian border. This is the site where, in the 1950s and 1960s, resistance to chloroquine and sulfadoxine-pyrimethamine originated, before it spread across Asia and to Africa, contributing to millions of deaths from malaria⇑.
After previous reports of possible artemisinin resistance, two open label randomised trials of 40 patients each, one in Pailin, western Cambodia, and the other in Wang Pha, northwestern Thailand, compared the efficacies of two treatments for uncomplicated falciparum malaria—oral artesunate for seven days, and artesunate for three days followed by two doses of mefloquine.
The trials showed that in vivo susceptibility to artesunate is reduced in Plasmodium falciparum found in Cambodia compared with parasites from Thailand. The median parasite clearance time was 48 hours in Thailand, compared with 84 hours in Cambodia. Rates of recrudescence in the monotherapy and combined groups, respectively, were two of 20 patients and one of 20 in Thailand, and six of 20 and one of 20 in Cambodia. The difference could not be explained by age, pharmacokinetics, in vitro sensitivity tests, or molecular correlates of P falciparum drug resistance.
The authors call for urgent containment measures to limit the spread of resistant parasites.
New approach shows promise for a vaccine against malaria
Immunity against malaria is difficult to achieve, either by natural exposure or by vaccination, and we still don’t know what precisely constitutes antimalarial immunity in humans⇑. Previous attempts to develop a vaccine revolved around the use of irradiated infected mosquitoes; however, a minimum of 1000 mosquito bites over five or more immunisation sessions is needed to induce immunity in volunteers—clearly an inappropriate method for routine use. Some hope comes from the development of subunit …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record







CiteULike
Connotea
Del.icio.us
Digg
Facebook
Mendeley
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: Ventilator associated pneumonia
Published 30 May 2012
Re: Restless legs syndrome
Published 30 May 2012
Author's reply
Published 30 May 2012
Re: Full access to trial data holds many benefits and a few pitfalls, conference hears
Published 30 May 2012
Restless Legs Syndrome: Fact or Fiction
Published 30 May 2012
Most responses
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 (12 responses)
Published 10 May 2012 - 23:32
The psychiatric oligarchs who medicalise normality (9 responses)
Published 2 May 2012 - 15:42
Are doctors justified in taking industrial action in defence of their pensions? No (8 responses)
Published 8 May 2012 - 12:21
Are doctors justified in taking industrial action in defence of their pensions? Yes (8 responses)
Published 8 May 2012 - 12:21
The hardest thing: admitting error (7 responses)
Published 2 May 2012 - 12:27